Sequential high- and low-dose systemic corticosteroid therapy for severe childhood alopecia areata;Kombinierte Hoch-/Niedrig-Dosis-Therapie mit systemischen Glukokor­tikoiden bei schweren Verlaufsformen der Alopecia areata im Kindesalter

JDDG - Journal of the German Society of Dermatology

Volumn 15, Issue 1, 2017, Pages 42-47

  Jahn Bassler, Karin ^a   Bauer, Wolfgang Michael ^a   Karlhofer, Franz ^a   Vossen, Matthias G ^b   Stingl, Georg ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; PREDNISOLONE; GLUCOCORTICOID; CORTICOSTEROID;

ACNE; ALOPECIA; ALOPECIA AREATA; ALOPECIA TOTALIS; ALOPECIA UNIVERSALIS; ARTICLE; BLOOD PRESSURE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FOREHEAD; GLUCOSE BLOOD LEVEL; HAIR GROWTH; HUMAN; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; OBSERVATIONAL STUDY; OPEN STUDY; PRESCHOOL CHILD; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN; ACNE VULGARIS; ADOLESCENT; AUSTRIA; BODY WEIGHT; CHEMICALLY INDUCED; CUSHING SYNDROME; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; LONG TERM CARE; TREATMENT OUTCOME; HAIR; RECURRENT DISEASE; TREATMENT FAILURE;

ACNE VULGARIS; ADOLESCENT; ALOPECIA AREATA; AUSTRIA; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CUSHING SYNDROME; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; HUMANS; LONG-TERM CARE; MALE; PREDNISOLONE; TREATMENT OUTCOME; ADRENAL CORTEX HORMONES; HAIR; PULSE THERAPY, DRUG; RECURRENCE; TREATMENT FAILURE;

EID: 85011604865     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/ddg.12875     Document Type: Article

References (42)

1. Ghanizadeh A, Ayoobzadehshirazi A. A review of psychiatric disorders comorbidities in patients with alopecia areata. Int J Trichology 2014; 6: 2–4.
2. Hordinsky MK. Overview of alopecia areata. J Investig Dermatol Symp Proc 2013; 16: S13–5.
3. Safavi KH, Muller SA, Suman VJ et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 1995; 70: 628–33.
4. Safavi K. Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. Arch Dermatol 1992; 128: 702.
5. Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med 2012; 366: 1515–25.
6. Ikeda T. A new classification of alopecia areata. Dermatologica 1965; 131: 421–45.
7. Barahmani N, Schabath MB, Duvic M, National Alopecia Areata R. History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol 2009; 61: 581–91.
8. Wu MC, Yang CC, Tsai RY, Chen WC. Late-onset alopecia areata: a retrospective study of 73 patients from Taiwan. J Eur Acad Dermatol Venereol 2013; 27: 468–72.
9. Nanda A, Al-Fouzan AS, Al-Hasawi F. Alopecia areata in children: a clinical profile. Pediatr Dermatol 2002; 19: 482–5.
10. Messenger AG, McKillop J, Farrant P et al. British Association of Dermatologists’ guidelines for the management of alopecia areata 2012. Br J Dermatol 2012; 166: 916–26.
11. De Waard-van der Spek FB, Oranje AP, De Raeymaecker DM, Peereboom-Wynia JD. Juvenile versus maturity-onset alopecia areata – a comparative retrospective clinical study. Clin Exp Dermatol 1989; 14(6): 429–33.
12. Goh C, Finkel M, Christos PJ, Sinha AA. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol 2006; 20: 1055–60.
13. Ertekin V, Tosun MS, Erdem T. Screening of celiac disease in children with alopecia areata. Indian J Dermatol 2014; 59: 317.
14. Mahamid M, Abu-Elhija O, Samamra M et al. Association between vitamin D levels and alopecia areata. Isr Med Assoc J 2014; 16: 367–70.
15. Friedland R, Tal R, Lapidoth M et al. Pulse corticosteroid therapy for alopecia areata in children: a retrospective study. Dermatology 2013; 227: 37–44.
16. Hubiche T, Leaute-Labreze C, Taieb A, Boralevi F. Poor long term outcome of severe alopecia areata in children treated with high dose pulse corticosteroid therapy. Br J Dermatol 2008; 158: 1136–7.
17. Sharma VK, Muralidhar S. Treatment of widespread alopecia areata in young patients with monthly oral corticosteroid pulse. Pediatr Dermatol 1998; 15: 313–7.
18. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987; 317: 1098.
19. Roche Lexikon Medizin. 5. Edition, Urban & Fischer Verlag, München und Jena, 2006.
20. Rakowska A, Slowinska M, Olszewska M, Rudnicka L. New trichoscopy findings in trichotillomania: flame hairs, V-sign, hook hairs, hair powder, tulip hairs. Acta Derm Venereol 2014; 94: 303–6.
21. Lalosevic J, Gajic-Veljic M, Bonaci-Nikolic B, Nikolic M. Combined oral pulse and topical corticosteroid therapy for severe alopecia areata in children: a long-term follow-up study. Dermatol Ther 2015; 28(5): 309–17.
22. Tosti A, Guidetti MS, Bardazzi F, Misciali C. Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis. J Am Acad Dermatol 1996; 35: 199–201.
23. Royer M, Bodemer C, Vabres P et al. Efficacy and tolerability of methotrexate in severe childhood alopecia areata. Br J Dermatol 2011; 165: 407–10.
24. Joly P. The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis. J Am Acad Dermatol 2006; 55: 632–6.
25. Kar BR, Handa S, Dogra S, Kumar B. Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J Am Acad Dermatol 2005; 52: 287–90.
26. Acikgoz G, Ozmen I, Cayirli M et al. Pulse methylprednisolone therapy for the treatment of extensive alopecia areata. J Dermatolog Treat 2014; 25: 164–6.
27. Olsen EA, Carson SC, Turney EA. Systemic steroids with or without 2 % topical minoxidil in the treatment of alopecia areata. Arch Dermatol 1992; 128: 1467–73.
28. Sharma VK, Gupta S. Twice weekly 5 mg dexamethasone oral pulse in the treatment of extensive alopecia areata. J Dermatol 1999; 26: 562–5.
29. Luggen P, Hunziker T. High-dose intravenous corticosteroid pulse therapy in alopecia areata: own experience compared with the literature. J Dtsch Dermatol Ges 2008; 6: 375–8.
30. McElwee KJ, Freyschmidt-Paul P, Hoffmann R et al. Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)/CD25(-) cells promote systemic alopecia areata and CD4(+)/CD25(+) cells blockade disease onset in the C3H/HeJ mouse model. J Invest Dermatol 2005; 124: 947–57.
31. Gilhar A, Pillar T, Assay B, David M. Failure of passive transfer of serum from patients with alopecia areata and alopecia universalis to inhibit hair growth in transplants of human scalp skin grafted on to nude mice. Br J Dermatol 1992; 126: 166–71.
32. Freyschmidt-Paul P, Happle R, Hoffman R. Alopecia areata in animal models – new insights into pathogenesis and treatment of a T cell-mediated autoimmune disorder. J Dtsch Dermatol Ges 2004; 2: 260–73.
33. Gilhar A, Landau M, Assy B et al. Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice. J Invest Dermatol 2001; 117: 1357–62.
34. Paus R, Nickoloff BJ, Ito T. A “hairy” privilege. Trends Immunol 2005; 26: 32–40.
35. Meyer KC, Klatte JE, Dinh HV et al. Evidence that the bulge region is a site of relative immune privilege in human hair follicles. Br J Dermatol 2008; 159: 1077–85.
36. Ito T, Ito N, Saatoff M et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol 2008; 128: 1196–206.
37. Shin BS, Furuhashi T, Nakamura M et al. Impaired inhibitory function of circulating CD4+CD25+ regulatory T cells in alopecia areata. J Dermatol Sci 2013; 70: 141–3.
38. Harries MJ, Paus R. The pathogenesis of primary cicatricial alopecias. Am J Pathol 2010; 177: 2152–62.
39. Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol 2014; 134: 2988–90.
40. Xing L, Dai Z, Jabbari A et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 2014; 20: 1043–9.
41. Castela E, Le Duff F, Butori C et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA dermatology 2014; 150: 748–51.
42. Stary G, Klein I, Bauer W et al. Glucocorticosteroids modify Langerhans cells to produce TGF-beta and expand regulatory T cells. J Immunol 2011; 186: 103–12.